Study identifier:D0102C00003
ClinicalTrials.gov identifier:N/A
EudraCT identifier:N/A
CTIS identifier:N/A
A Phase I/II Multi-centre Study of AZD8931 in Combination with Weekly Paclitaxel to Assess the Safety, Tolerability, Pharmacokinetics and Efficacy in Patients with Advanced Solid Tumours and in a Selected Population with Low HER2-expressing Locally Recurrent and/or Metastatic Breast Cancer
Neoplasms
Phase 1/2
No
AZD8931, Paclitaxel, Placebo
All
330
Interventional
18 Years - 150 Years
Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind
Primary Purpose: Treatment
Verified 01 Jun 2015 by AstraZeneca
AstraZeneca
-
The main purpose of this study is to determine if AZD8931 can improve the efficacy of standard chemotherapy for the treatment of advanced breast cancer. This study will be conducted in 2 parts: the first part (phase I) will determine a dose of AZD8931 that can be safely administered with paclitaxel chemotherapy. The second part (phase II) will determine the efficacy and safety of AZD8931 in combination with paclitaxel chemotherapy in breast cancer.
Location
Location
Brussels (Jette), Belgium
Location
Namur, Belgium
Location
Sint-Niklaas, Belgium
Location
Leuven, Belgium
Location
Sofia, Bulgaria
Location
Stara Zagora, Bulgaria
Location
Varna, Bulgaria
Location
Vratza, Bulgaria
Arms | Assigned Interventions |
---|---|
Experimental: 1 AZD8931 plus Paclitaxel | Drug: AZD8931 Tablet Oral bid Drug: Paclitaxel IV once weekly for 3 weeks followed by a week off (repeated cycles) Other Name: Taxol |
Placebo Comparator: 2 Placebo plus Paclitaxel | Drug: Paclitaxel IV once weekly for 3 weeks followed by a week off (repeated cycles) Other Name: Taxol Drug: Placebo Oral bid (twice daily) |
This information is not intended to replace the informed medical advice or medical treatments of a healthcare professional. Only a physician can determine if a specific medicine is the correct treatment for a particular patient. If you have questions regarding any information contained in this site, you must consult a suitably qualified healthcare professional. Before prescribing any AstraZeneca products, Healthcare Professionals should view their country specific information.